Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
meloxicam, Quantity: 15 mg
Cipla Australia Pty Ltd
Tablet, uncoated
Excipient Ingredients: microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; maize starch; sodium citrate dihydrate; colloidal anhydrous silica; magnesium stearate
Oral
30 tablets
(S4) Prescription Only Medicine
Symptomatic treatment of osteoarthritis and rheumatoid arthritis.
Visual Identification: Pale-yellow, circular 10 mm, flat bevelled uncoated tablet, with a central break-line on one side and plain on other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2018-04-03
CIPLA MELOXICAM 1 CIPLA MELOXICAM CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING CIPLA MELOXICAM? CIPLA MELOXICAM contains the active ingredient meloxicam. CIPLA MELOXICAM is used to treat the symptoms of osteoarthritis and rheumatoid arthritis. For more information, see Section 1. Why am I using CIPLA MELOXICAM? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE CIPLA MELOXICAM? Do not use if you have ever had an allergic reaction to meloxicam or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. Do not use at all during the last three months of pregnancy. For more information, see Section 2. What should I know before I use CIPLA MELOXICAM? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with CIPLA MELOXICAM and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE CIPLA MELOXICAM? • For the treatment of osteoarthritis: The usual dose of CIPLA MELOXICAM is 7.5 mg, taken as a single dose each day. • For the treatment of rheumatoid arthritis: The usual dose of CIPLA MELOXICAM is 15 mg taken as a single dose each day. Swallow the tablets whole with a full glass of water. More instructions can be found in Section 4. How do I use CIPLA MELOXICAM? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING CIPLA MELOXICAM? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist when you visit that you are using CIPLA MELOXICAM. • If you are going to have surgery, tell the surgeon or anaesthetist that you are taking CIPLA MELOXICAM. CIPLA MELOXICAM can slow down blood clotting. THINGS YOU SHOULD NOT DO • Do not stop taking your medicine or lower the dosage without checking with your doctor. DRIVING Soma hati kamili
AUSTRALIAN PRODUCT INFORMATION - CIPLA MELOXICAM (MELOXICAM) 1 NAME OF THE MEDICINE Meloxicam 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CIPLA MELOXICAM 7.5 MG Each tablet of CIPLA MELOXICAM contains 7.5 mg of meloxicam CIPLA MELOXICAM 15 MG Each tablet of CIPLA MELOXICAM contains 15 mg of meloxicam Excipients with known effect: Contains lactose For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Tablets CIPLA MELOXICAM tablets 7.5mg (pale yellow, circular, flat bevelled uncoated tablet with a central break-line on one side and plain on the other). CIPLA MELOXICAM tablets 15 mg (pale yellow, circular, flat bevelled uncoated tablet with a central break-line on one side and plain on the other). 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of osteoarthritis and rheumatoid arthritis. 4.2 DOSE AND METHOD OF ADMINISTRATION CIPLA MELOXICAM should be used at the lowest dose and for the shortest duration consistent with effective treatment. The maximum recommended daily dose of CIPLA MELOXICAM is 15 mg. A dose of 15 mg/day should not be exceeded. As a dose for children has not been established, use should be restricted to adults (see Section 4.4 Special Warnings and Precautions for Use - Paediatric Use). The dose of CIPLA MELOXICAM in patients with end-stage renal failure on haemodialysis should not exceed 7.5 mg/day (see Section 5.2 Pharmacokinetic Properties – Renal Impairment and Haemodialysis). No dose reduction is required in patients with mild or moderate renal impairment (i.e., in patients with a creatinine clearance of greater than 25 mL/min) nor in patients with mild to moderate hepatic impairment. In non-dialysed patients with severe renal impairment CIPLA MELOXICAM is contraindicated (see Section 4.3 Contraindications). In patients with increased risks of adverse reactions, e.g. a history of gastrointestinal disease or risk factors for cardiovascular disease, the treatment should be started at a dose of 7.5 mg/day and increased to 15 mg/day on Soma hati kamili